Abstract WP415: Desirable LDL-cholesterol Levels For Preventing Stroke Recurrence -Subanalysis of J-STARS

Background & Aims: The risk reduction of major vascular events per 1.0 mmol/L further reduction in LDL-cholesterol did not depend on the baseline LDL-cholesterol concentration. However, the desirable LDL-cholesterol level for preventing stroke recurrence has still not been defined. To define desirable LDL-cholesterol levels for preventing stroke recurrence, subanalysis was made on J-STARS. Methods: In J-STARS, patients with non-cardioembolic ischemic stroke (atherothrombotic infarction, lacunar infarction, infarction of undetermined etiology) were randomized into the pravastatin group (10 mg/day, n=793) or the control group (n=785) received no statin treatment. The primary endpoint was the recurrence of stroke and transient ischemic attack (TIA). The subjects were divided based on tertile of LDL-cholesterol at enrollment, mean during observation period, just before the event, and their differences. Adjusted hazard ratio (HR) (95% confidence interval [CI]) were analyzed for each tertile adjusting the factors that showed inter-group differences, including age, body mass index, hypertension, diabetes mellitus, duration until an enrollment following stroke events, and the usage of statin. Reference was set at the highest tertile. Results: Adjusted HR of stroke and TIA lowered in accordance with the reduction of LDL-cholesterol from enrollment both to mean during observation period and to just before the event (p<0.001 and <0.001 for trend). The occurrence of intracranial hemorrhage showed a significantly low relative risk in the middle tertile of LDL-cholesterol reduction (2.0 to 28.0 mg/dl) from enrollment to just before the event (adjusted HR 0.15 [95%CI 0.03, 0.68]). But, this risk reduction of intracranial hemorrhage was diminished in the lowest tertile. And, a relatively high risk of intracranial hemorrhage was observed in the lowest tertile of LDL-cholesterol (less than 101.0 mg/dl) just before the event (2.68 [0.82, 8.77]). Conclusions: The composite risk of stroke and TIA reduced according to the reduction of LDL-cholesterol adjusting the statin usage. The risk of intracranial hemorrhage reduced with mild reduction of LDL-cholesterol, but not when LDL-cholesterol reduced more than 28.0 mg/dl. (NCT00221104)

Download Full-text

Cholesterol lowering in pigs through enhanced bacterial bile salt hydrolase activity

British Journal Of Nutrition ◽

10.1079/bjn19980030 ◽

1998 ◽

Vol 79 (2) ◽

pp. 185-194 ◽

Cited By ~ 108

Author(s):

I. De Smet ◽

P. De Boever ◽

W. Verstraete

Keyword(s):

Bile Salt ◽

Ldl Cholesterol ◽

Lactobacillus Reuteri ◽

Plasma Cholesterol ◽

Hdl Cholesterol ◽

Blood Cholesterol ◽

Cholesterol Concentration ◽

Control Group ◽

Bile Salt Hydrolase ◽

Cholesterol Levels

The effect of feeding liveLactobacillus reutericells containing active bile salt hydrolase (BSH) on plasma cholesterol levels was studied in pigs. During an experiment lasting 13 weeks, twenty pigs were fed on a high-fat, high-cholesterol, low-fibre diet for the first 10 weeks, and a regular pig diet for the last 3 weeks. One group of animals received, twice daily, 11·25 (SD 0·16) log10colony forming units of the potential probiotic bacteria for 4 weeks (from week 3 until week 7). From week 8 onwards, the treated group was again fed on the same diet as the control group without additions. The total faecalLactobacilluscounts were only significantly higher in the treated pigs during the first 2 weeks ofL. reuterifeeding. Based on limited data, it was suggested that the administeredLactobacillusspecies had caused a temporary shift within the indigenousLactobacilluspopulation rather than permanently colonizing the intestinal tract. The probiotic feeding brought about significant lowering (P≤ 0·05) of total and LDL-cholesterol concentrations in the treated pigs compared with the control pigs, while no change in HDL-cholesterol concentration was observed. The data for faecal output of neutral sterols and bile salts were highly variable between the animals of each group, yet they indicated an increased output in the treated pigs. Although the blood cholesterol levels went up in both groups during the 3 weeks following theLactobacillusadministration period, significantly lower serum total and LDL-cholesterol levels were observed in the treated pigs. During the final 3 weeks of normalization to the regular diet, cholesterol concentrations significantly decreased in both animal groups and the differences in total and LDL-cholesterol concentrations between the groups largely disappeared.

Download Full-text

Abstract TP438: Japanese versus Non-Japanese Patients With Transient Ischemic Attack or Minor Stroke: Five-Year Risk of Stroke and Vascular Events

Stroke ◽

10.1161/str.51.suppl_1.tp438 ◽

2020 ◽

Vol 51 (Suppl_1) ◽

Author(s):

Shinichiro Uchiyama ◽

Takao Hoshino ◽

Hugo Charles ◽

Kenji Kamiyama ◽

Taizen Nakase ◽

...

Keyword(s):

Intracranial Hemorrhage ◽

Transient Ischemic Attack ◽

Japanese Patients ◽

Minor Stroke ◽

Stroke Recurrence ◽

Large Artery ◽

Vascular Events ◽

Minor Ischemic Stroke ◽

Ischemic Attack

Background: We have reported 5-year risk of stroke and vascular events after a transient ischemic attack (TIA) or minor ischemic stroke in patients enrolled into the TIAregistry.org, which was an international multicenter-cooperative, prospective registry (N Engl J Med 2018;378:2182-90). We conducted subanalysis on the 5-year follow-up data of Japanese patients in comparison with non-Japanese patients. Methods: The patients were classified into two groups on ethnicity, Japanese (n=345) and non-Japanese (n=3502), and their 5-year event rates were compared. We also determined predictors of five-year stroke in both groups. Results: Death from vascular cause (0.9% vs 2.7%, HR 0.28, 95% CI 0.09-0.89, p=0.031) and death from any cause (7.8% vs 9.9%, HR 0.67, 95% CI 0.45-0.99, p=0.045) were fewer in Japanese patients than in non-Japanese patients, while stroke (13.9% vs 7.2%, HR 1.78, 95% CI 1.31-2.43, p<0.001) and intracranial hemorrhage (3.2% vs 0.8%, HR 3.61. 95% CI 1.78-7.30, p<0.001) were more common in Japanese than non-Japanese patients during five-year follow-up period. Caplan-Meyer curves at five-years showed that the rates of stroke was also significantly higher in Japanese than non-Japanese patients (log-rank test, p=0.001). Predictors for stroke recurrence at five years were large artery atherosclerosis (HR 1.81, 95% CI 1.31-2.52, p<0.001), cardioembolism (HR 1.71, 95% CI 1.18-2.47, p=0.004), multiple acute infarction (HR 1.77, 95% CI 1.27-2.45, p<0.001) and ABCD 2 score 6 or 7 (HR 1.96, 95% CI 1.38-2.78, p<0.001) in non-Japanese patients, although only large artery atherosclerosis (HR 3.28, 95% CI 1.13-9.54, p=0.029) was a predictor for stroke recurrence in Japanese patients. Conclusions: Recurrence of stroke and intracranial hemorrhage were more prevalent in Japanese than non-Japanese patients. Large artery atherosclerosis was a predictor for stroke recurrence not only in non-Japanese patients but also in Japanese patients.

Download Full-text

Abstract WP421: Pravastatin Can Reduce the Progression of Carotid Intima-media Complex Thickness: The Japan Statin Treatment Against Recurrent Stroke (J-STARS) Echo Study

Stroke ◽

10.1161/str.48.suppl_1.wp421 ◽

2017 ◽

Vol 48 (suppl_1) ◽

Author(s):

Masatoshi Koga ◽

Kazunori Toyoda ◽

Kazuo Minematsu ◽

Masahiro Yasaka ◽

Yoji Nagai ◽

...

Keyword(s):

Repeated Measures ◽

Recurrent Stroke ◽

Japanese Patients ◽

Statin Treatment ◽

Stroke Recurrence ◽

Control Group ◽

Open Label ◽

Usual Dose ◽

Reductase Inhibitors ◽

To Receive

Background and purpose: The preventive effect of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) on progression of carotid intima-media complex thickness (IMT) has been shown exclusively in non-stroke Western patients. The Japan Statin Treatment Against Recurrent Stroke (J-STARS) Echo Study aims to determine the effect of pravastatin on carotid IMT in Japanese patients with hyperlipidemia with noncardioembolic ischemic stroke. Methods: This is a substudy of the J-STARS, a multicenter, randomized, open-label, blinded-endpoint, parallel-group trial to examine whether pravastatin reduces stroke recurrence in patients with noncardioembolic stroke. The patients were randomized to receive pravastatin (10 mg daily, usual dose in Japan) (pravastatin group) or not to receive any statins (control group). Carotid ultrasonography was performed by well-trained certified examiners and the recorded data was measured centrally. The primary outcome was IMT change of the distal wall in a continuous 2-cm section on the central side of the common carotid artery bifurcation over 5 years of observation. The IMT change was compared using mixed models for repeated measures. Results: Of 1578 patients who were enrolled in the J-STARS, 864 were registered in this echo substudy. After excluding 71 without baseline ultrasonography, 793 (530 men, 66.4±8.3 years old) were analyzed. Of the 793 patients, 388 were randomly assigned to the pravastatin group and 405 to the control group. Baseline characteristics were not significantly different except baseline NIH Stroke Scale [median 0 (IQR 0-2) vs. 1 (0-2), p=0.019] between the two groups. The baseline IMT (mean±SD) was 0.887±0.155 mm in the pravastatin group and 0.887±0.152 mm in the control group (p=0.990). Each annual change of the IMT (mean±SD) over 5 years of observation was 0.011±0.085 mm, 0.023±0.114 mm, 0.017±0.114 mm, 0.018±0.118 mm and 0.021±0.116 mm in the pravastatin group and 0.008±0.074 mm (p=0.650), 0.020±0.087 mm (p=0.985), 0.017±0.097 mm (p=0.586), 0.030±0.113 mm (p=0.202) and 0.040±0.118 mm (p=0.018) in the control group. Conclusion: Japanese usual dose of pravastatin significantly reduced the progression of carotid mean IMT at 5 years in patients with noncardioembolic stroke.

Download Full-text

Abstract WP419: Secondary Prevention Of Cardiovascular Events With Lifestyle Intervention In Patients With Mild Ischemic Stroke - A Randomized Controlled Trial -

Stroke ◽

10.1161/str.44.suppl_1.awp419 ◽

2013 ◽

Vol 44 (suppl_1) ◽

Author(s):

Sumio Yamada ◽

Yuji Kono ◽

Kotaro Iwatsu ◽

Hisako Okumura ◽

Junko Yamaguchi ◽

...

Keyword(s):

Ischemic Stroke ◽

Lifestyle Intervention ◽

Lifestyle Modification ◽

Controlled Trial ◽

Intervention Group ◽

Stroke Recurrence ◽

Control Group ◽

Vascular Events ◽

Randomized Controlled ◽

New Onset

Introduction: Lifestyle modification is associated with a substantially decreased risk of cardiovascular events. However, the role of lifestyle intervention for the secondary prevention in patients with ischemic stroke (IS) is inadequately defined. We assessed the hypothesis that lifestyle intervention which comprised exercise, salt reduction and nutrition advice could reduce new onset of vascular events in patients with mild IS. Methods: We conducted a single-blind randomized controlled trial that enrolled 66 patients (45 men, 21 women; mean age, 63.5 yo) with acute mild ischemic stroke. The patients were randomly allocated to a lifestyle intervention group (n = 33) or control group (n = 33). We performed lifestyle interventions, which comprised exercise training, salt restriction and nutrition advice for 24 weeks. The primary endpoint was ospitalization due to stroke recurrence and new onset of coronary heart disease. We also evaluated blood pressure, serum lipid profile and hemoglobin A1c to compare the efficacy of the lifestyle modification intervention. Results: This trial was terminated earlier than expected because the prespecified early stopping rule for efficacy had been met. After 24 weeks intervention period, the intervention group showed a significant decrease in the clinic and home blood pressure and significant increase in the high density lipoprotein cholesterol (HDL-C) levels from the baseline to the 6-month assessment (clinic and home SBP, P <0.001; HDL-C, P =0.018), with significant differences between the randomized groups (clinic and home SBP, P <0.001; HDL-C, P =0.022). Median duration of follow-up was 2.9 years, 12 patients allocated the control group and 1 patient allocated the lifestyle intervention group had at least one major vascular event. A sequential plans analysis indicated that lifestyle intervention superior to control in interim analysis. Kaplan-Meier survival curves after log-rank test showed significant prognostic difference between randomized groups ( P =0.005). Conclusions: In conclusion, the results of this study indicate that lifestyle intervention is beneficial for preventing stroke recurrence and other vascular events.

Download Full-text

Atorvastatin normalizes endothelial function in healthy smokers

Clinical Science ◽

10.1042/cs20060033 ◽

2006 ◽

Vol 111 (1) ◽

pp. 87-91 ◽

Cited By ~ 15

Author(s):

Stefan Agewall ◽

Åsa Hernberg

Keyword(s):

Endothelial Function ◽

Low Density Lipoprotein ◽

Density Lipoprotein ◽

Statin Treatment ◽

Control Group ◽

Flow Mediated Dilation ◽

Atorvastatin Treatment ◽

Cholesterol Levels ◽

Smoking Group ◽

To Receive

Endothelial function is known to predict cardiovascular disease. The aim of the present study was to examine whether endothelial function in smokers with normal cholesterol levels could be normalized by treatment with 80 mg of atorvastatin in comparison with a control group. Healthy smokers (n=20) and non-smokers (n=20) were randomized to receive 80 mg of atorvastatin or placebo in an open randomized cross-over study, followed by measurement of endothelial functional [FMD (flow-mediated dilation)]. At baseline, smokers had a lower FMD compared with the non-smoking group (2.2±0.5 and 4.5±0.8% respectively; P<0.05). In the smoking group, FMD increased significantly (P<0.05) to 4.0±0.8% during treatment with atorvastatin and returned to basal levels during placebo (2.3±0.6%). In the non-smoking group, FMD was unaffected by both atorvastatin and placebo. The net change of total cholesterol or LDL (low-density lipoprotein)-cholesterol was not associated with the net change in FMD when the study group was considered as a whole or the smoking group was considered separately. In conclusion, improved endothelial function was observed in a group of smokers when they were received 80 mg of atorvastatin, whereas atorvastatin had no effect on endothelial function in the non-smoking group. The improved FMD among smokers was independent of the decrease in LDL-cholesterol during atorvastatin treatment. The results show that poor endothelial function in smokers with normal lipid levels can be improved by a statin treatment.

Download Full-text

PENGARUH PEMBERIAN KEFIR SUSU SAPI TERHADAP KADAR KOLESTEROL LDL TIKUS JANTAN SPRAGUE DAWLEY HIPERKOLESTEROLEMIA

Journal of Nutrition College ◽

10.14710/jnc.v1i1.386 ◽

2012 ◽

Vol 1 (1) ◽

pp. 358-364 ◽

Cited By ~ 1

Author(s):

Sandy Eka Pratama ◽

Enny Probosari

Keyword(s):

Ldl Cholesterol ◽

Direct Method ◽

Wilcoxon Test ◽

Control Group ◽

Sprague Dawley ◽

Control Group Design ◽

Cholesterol Levels ◽

Sprague Dawley Rats ◽

Post Test ◽

Cause Of Deaths

Background: Hypercholesterolemia is a main risk factor of cardiovascular disease that remains the higher cause of deaths in the world. Milk kefir contains lactic acid bacteria which can reduce LDL cholesterol. The objective of this study was to determine the effect of milk kefir on LDL cholesterol levels in male Sprague dawley hypercholesterolemia rats. Methods: This research was true-experimental using pre-post test with randomized control group design. Subjects were male Sprague dawley rats, inducted hypercholesterolemia, given milk kefir diet using 1,5 ml, 2 ml, and 3 ml dosage for 15 days. The LDL cholesterol levels were measured by direct method using homogenous enzymatic LDL cholesterol. Normality of the data were tested by Shapiro Wilk test. Data were analyzed by Wilcoxon test and Kruskall-Wallis continued by Mann-Whitney test. Result: The study revealed that milk kefir of dosage 2 ml/day decreased LDL cholesterol significantly (p<0,05) from 196,57 ± 84,11 mg/dl to 38,95 ± 18,22 mg/dl and also for 3 ml/day decreased LDL cholesterol significantly (p<0,05) from 100,14 ± 36,20 mg/dl to 26,91 ± 9,93 mg/dl. Other dosage of 1,5 ml/day is not significantly decrease LDL cholesterol level. Conclusion: Milk kefir able to reduce LDL cholesterol levels in all groups. By giving mik kefir 2 ml/day and 3ml/day during 15 days able to reduce LDL cholesterol levels 80,18% and 73,12%.

Download Full-text

PENGARUH PEMBERIAN JUS BUAH BELIMBING WULUH (AVERRHOA BILIMBI L.) TERHADAP KADAR KOLESTEROL LDL DARAH TIKUS PUTIH (RATTUS NORVEGICUS) JANTAN GALUR WISTAR DENGAN DIET TINGGI LEMAK

Jurnal Ilmiah Kedokteran Wijaya Kusuma ◽

10.30742/jikw.v8i2.572 ◽

2019 ◽

Vol 8 (2) ◽

pp. 35-41

Author(s):

Kartika Dwi Rahminiwati ◽

◽

IGM Antara Hambarsika ◽

Fitri Handajani ◽

◽

...

Keyword(s):

Cholesterol Level ◽

High Fat Diet ◽

Ldl Cholesterol ◽

Positive Control ◽

Negative Control ◽

Positive Control Group ◽

Control Group ◽

High Fat ◽

Cholesterol Levels ◽

The Mean

A high-fat diet can increase lipoprotein levels, total cholesterol, (Low Density Lipoprotein) LDL, and triglycerides. Starfruit has saponin and flavonoid compounds which are expected to reducing LDL cholesterol levels. The aim of the study was to determine the effect of starfruit juice on lowering the blood cholesterol LDL of Wistar rats fed with high-fat diet. Experimental study with post-test only control group design. As many as 24 male white rats from the Wistar strain were divided into 3 groups: negative control groups (K-) that were given standard feed for 28 days; positive control group (K+) who were given a high-fat diet for 28 days; the treatment group (KP) was given a high-fat diet for 28 days and on the 15th day 28th they were given a starfruit juice with a dose of 4ml / 200grBB / day. Day 29 measured LDL cholesterol. The statistic test showed a significant increase in LDL cholesterol levels (p=0.001) in the positive control group (x=12.125±2.642 mg/dL) compared to the negative control group (x=7.625±1.506 mg/dL). There was no significant different the mean cholesterol level of the treatment group (x=11±1.927) compared to the mean LDL cholesterol level of the positive control group (x=12.125±2.642). A high-fat diet significantly increases the mean LDL cholesterol level. Starfruit juice did not significantly reduce LDL cholesterol level.

Download Full-text

Electroacupuncture Therapy for Weight Loss Reduces Serum Total Cholesterol, Triglycerides, and LDL Cholesterol Levels in Obese Women

The American Journal of Chinese Medicine ◽

10.1142/s0192415x05003132 ◽

2005 ◽

Vol 33 (04) ◽

pp. 525-533 ◽

Cited By ~ 66

Author(s):

Mehmet Tuǧrul Cabıoǧlu ◽

Neyhan Ergene

Keyword(s):

Total Cholesterol ◽

Weight Reduction ◽

Ldl Cholesterol ◽

Density Lipoprotein ◽

The Body ◽

Serum Total Cholesterol ◽

Control Group ◽

Obese Women ◽

Diet Restriction ◽

Cholesterol Levels

Our purpose in this study was to investigate the effect of acupuncture therapy on body weight and on levels of the serum total cholesterol, triglyceride, high-density lipoprotein (HDL) cholesterol and low-density lipoprotein (LDL) cholesterol in obese women. Fifty-five women were studied in three groups as follows: (1) control group ( n = 12; mean age = 43.3 ± 4.3, and mean body mass index { BMI } = 32.2 ± 3.4); (2) electroacupuncture (EA) ( n = 22; mean age = 39.8 ± 5.3, and BMI = 34.8 ± 3.3); and (3) diet restriction ( n = 21; mean age = 42.7 ± 3.9, and BMI = 34.9 ± 3.3). EA was performed using the ear points, Sanjiao (Hungry) and Shen Men (Stomach), and the body points, LI 4, LI 11, St 25, St 36, St 44 and Liv 3, once daily, for 30 minutes, for 20 days, whereas patients on diet restriction had a 1425 Kcal diet program, that consisted of 1425 Kcal daily for 20 days. There was a 4.8% weight reduction in patients with EA application, whereas patients on diet restriction had a 2.5% weight reduction. There were significant decreases in total cholesterol and triglyceride levels in EA and diet groups compared with the control group ( p < 0.05 in both cases). Furthermore, there was a decrease in LDL levels in the EA group compared with the control group ( p < 0.05). No significant changes could be found in HDL levels among the three groups. Our results suggest that EA application in obese women may decrease the serum total cholesterol, triglyceride, and LDL cholesterol levels by increasing the serum beta endorphin level. This lipolytic effect of EA may also reduce the morbidity of obesity by mobilizing the energy stores that result in weight reduction.

Download Full-text

Effects of long-term plant sterol or stanol ester consumption on lipid and lipoprotein metabolism in subjects on statin treatment

British Journal Of Nutrition ◽

10.1017/s0007114508966113 ◽

2008 ◽

Vol 100 (5) ◽

pp. 937-941 ◽

Cited By ~ 51

Author(s):

Ariënne de Jong ◽

Jogchum Plat ◽

Dieter Lütjohann ◽

Ronald P. Mensink

Keyword(s):

Bile Acid ◽

Plant Sterol ◽

Ldl Cholesterol ◽

Cholesterol Metabolism ◽

Acid Synthesis ◽

Statin Treatment ◽

Bile Acid Synthesis ◽

Control Group ◽

Stanol Ester

Consumption of plant sterol- or stanol-enriched margarines by statin users results in an additional LDL-cholesterol reduction of approximately 10 %, which may be larger than the average decrease of 3–7 % achieved by doubling the statin dose. However, whether this effect persists in the long term is not known. Therefore, we examined in patients already on stable statin treatment the effects of 85 weeks of plant sterol and stanol ester consumption on the serum lipoprotein profile, cholesterol metabolism, and bile acid synthesis. For this, a double-blind randomised trial was designed in which fifty-four patients consumed a control margarine with no added plant sterols or stanols for 5 weeks (run-in period). For the next 85 weeks, seventeen subjects continued with the control margarine and the other two groups with either a plant sterol (n18) or plant stanol (n19) (2·5 g/d each) ester-enriched margarine. Blood was sampled at the end of the run-in period and every 20 weeks during the intervention period. Compared with the control group, plant sterol and stanol ester consumption reduced LDL-cholesterol by 0·28 mmol/l (or 8·7 %;P = 0·08) and 0·42 mmol/l (13·1 %;P = 0·006) respectively after 85 weeks. No effects were found on plasma concentrations of oxysterols or 7α-hydroxy-4-cholesten-3-one, a bile acid synthesis marker. We conclude that long-term consumption of both plant sterol and stanol esters effectively lowered LDL-cholesterol concentrations in statin users.

Download Full-text

Patient adherence to statin therapy within 12 months after coronary stenting depending on regular or remote monitoring

European Journal of Preventive Cardiology ◽

10.1093/eurjpc/zwab061.068 ◽

2021 ◽

Vol 28 (Supplement_1) ◽

Author(s):

A Osokina ◽

A Filatova ◽

A Potekhina ◽

A Shchinova ◽

S Provatorov

Keyword(s):

Statin Therapy ◽

Remote Monitoring ◽

Ldl Cholesterol ◽

Patient Adherence ◽

Control Group ◽

Cholesterol Levels ◽

Outpatient Visits ◽

Group 3 ◽

Group 2 ◽

Group 1

Abstract Funding Acknowledgements Type of funding sources: Other. Main funding source(s): Russian Ministry of Health Background. Low adherence to statins remains a challenge in the treatment of patients with cardiovascular diseases. Some patients who underwent coronary stenting (CS) are unavailable for regular follow-up with outpatient visits. The ability to remotely monitor patients after CS may facilitate adherence to treatment, achieve target low density lipoprotein (LDL) cholesterol levels and early detection of adverse events. We aimed to evaluate the adherence to statin therapy in patients after CS receiving remote monitoring or care with outpatient visits. Methods. We enrolled 279 consecutive stable CAD/silent myocardial ischemia patients (61.5 ± 9.5 years) who underwent CS. The patients were randomized into groups of regular outpatient visits (group 1, n = 96), remote monitoring (group 2, n = 95) and control group (group 3, n = 88). The visits (cardio exam and blood testing) and remote monitoring (videoconference, telephone care and blood tests interpretation) were performed at 1, 3, 6 and 12 months after CS for groups 1 and 2. Patients in the control group were cared by a physician at the residence place, the contact with the study coordinator was performed at baseline and 12 months after CS. Adherence to the prescribed medical therapy based on the four-item Morisky Green Levine Medication Adherence Scale was assessed at each contact with the study coordinator. Results. Patient adherence to statin therapy 12 months after CS was 53.6% for group 1, 55.8% for group 2 and 24.4% for group 3 (p < 0.05 for group 3 versus groups 1 and 2). In group 1 26.9/36.5/31.7/37.4*/41.3*% of patients achieved target LDL level at baseline/1mo/3mo/6mo/12mo, respectively (р<0.05 vs. baseline). In group 2 - 35.8/36.8/40.0/51.6*/57.9*% of patients (р<0.05 vs. baseline). In group 3 25.5/28.2% of patients achieved target LDL level at baseline/12mo, respectively. The significant decrease in LDL cholesterol levels between baseline and 12mo values was observed in groups 1 and 2 (p < 0.05). No differences were observed in group 3. Conclusion. The groups of patients receiving remote monitoring or care with outpatient visits demonstrate the same increase in the proportion of patients that achieved target LDL cholesterol levels within 12 months after CS. The remote monitoring is a safe strategy for improving and maintaining the adherence to statins in patients after CS.

Download Full-text